Drug Trial Radar · NCT06007183
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
715
Actual
Start
Aug 30, 2023
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3 or 4 years post-initial CHIKV VLP vaccination.
Conditions
- Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine boosterBiological
CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40 µg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
Placebo boosterBiological
Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants maintaining a preboost anti-CHIKV SNA titer ≥100 at yearly intervals up to 5 years post-initial vaccinationTime frame: 5 years post-initial vaccination in feeder study EBSI-CV-317-004 or EBSI-CV317-005 until booster
- Proportion of vaccine boosted participants with composite booster response at 21 days after booster vaccinationTime frame: 21 days after booster vaccination
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Alliance for Multispecialty Research, LLC
Mobile, Alabama
Alliance for Multispecialty Research, LLC
Tempe, Arizona
Optimal Research, LLC
Melbourne, Florida
Suncoast Research Associates, LLC
Miami, Florida
Synexus Clinical Research US, Inc.
Chicago, Illinois
Optimal Research, LLC
Peoria, Illinois
Alliance for Multispecialty Research, LLC
Newton, Kansas
Alliance for Multispecialty Research, LLC
Wichita, Kansas
Alliance for Multispecialty Research, LLC
Lexington, Kentucky
Alliance for Multispecialty Research, LLC
Kansas City, Missouri
Wr-Crcn, Llc
Las Vegas, Nevada
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada
Rochester Clinical Research, LLC
Rochester, New York
M3 Wake Research Inc.
Raleigh, North Carolina
Velocity Clinical Research, Cleveland
Cleveland, Ohio
Lynn Institute of Norman
Norman, Oklahoma
Velocity Clinical Research, Medford
Medford, Oregon
Velocity Clinical Research, Providence
East Greenwich, Rhode Island
Velocity Clinical Research, Austin
Cedar Park, Texas
DM Clinical Research
Houston, Texas
BFHC Research, LLC
San Antonio, Texas
DM Clinical Research
Tomball, Texas
Velocity Clinical Research, Salt Lake City
West Jordan, Utah
Alliance for Multispecialty Research, LLC
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.